SINOTHERAPEUTICS(688247.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
SINOTHERAPEUTICS
688247.SH
Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company’s products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules. The company also provides bupropion hydrochloride extended-release tablets, and paroxetine and pregabalin extended-release tablets; propafenone hydrochloride extended-release capsules; and sevelamer carbonate tablets.
3.097 T
688247.SHMarket value -Rank by Market Cap -/-

Financial Score

22/01/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking60/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.75%B
    • Profit Margin20.52%A
    • Gross Margin40.90%B
  • Growth ScoreC
    • Revenue YoY6.98%C
    • Net Profit YoY-10.02%D
    • Total Assets YoY1.88%C
    • Net Assets YoY5.73%B
  • Cash ScoreC
    • Cash Flow Margin487.35%C
    • OCF YoY6.98%C
  • Operating ScoreD
    • Turnover0.33D
  • Debt ScoreA
    • Gearing Ratio10.19%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SINOTHERAPEUTICS released its performance for the first three quarters, with a net profit attributable to the parent company of 63.46 million yuan, a year-on-year decrease of 31.45%

    According to the Zhitong Finance APP, SINOTHERAPEUTICS disclosed its third-quarter report for 2025. The company achieved revenue of 331 million yuan in the first three quarters, a year-on-year decrease of 8.59%; the net profit attributable to the parent company was 63.46 million yuan, a year-on-year decrease of 31.45%; the net profit excluding non-recurring gains and losses was 53.88 million yuan, a year-on-year decrease of 36.64%; the basic earnings per share were 0.14 yuan

    Zhitong·
    SH
    688247
    +0.28%
    Zhitong·
    SH
    688247
    +0.28%

    SINOTHERAPEUTICS: The company's products are expected to be selected for the national centralized procurement of drugs

    SINOTHERAPEUTICS announced that recently, the company participated in the bidding organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. According to the "Proposed Selection Results Announcement for National Centralized Drug Procurement" released by the procurement office on October 28, 2025, the company's product Olaparib tablets is proposed to be selected for this centralized procurement

    Zhitong·
    SH
    688247
    +0.28%
    Zhitong·
    SH
    688247
    +0.28%

    SINOTHERAPEUTICS: The Sitagliptin Metformin Extended-Release Tablets have received approval from the U.S. FDA

    SINOTHERAPEUTICS announced that its generic drug application for Sitagliptin Metformin Extended-Release Tablets has received temporary approval from the U.S. FDA. The drug was developed by MERCK SHARPDOHME and is used to improve blood sugar control in adults with type 2 diabetes

    Zhitong·
    SH
    688247
    +0.28%
    Zhitong·
    SH
    688247
    +0.28%

    Wu Huafeng, Deputy General Manager of Shanghai SINOTHERAPEUTICS, has resigned early for personal reasons

    On September 30, 2025, the board of directors of Shanghai SINOTHERAPEUTICS Co., Ltd. received a written resignation letter from Vice President Wu Huafeng. Wu Huafeng applied to resign from the position of Vice President for personal reasons, with the original term set to end on May 30, 2026. After resigning, he will no longer hold any position in the company. His resignation will take effect from the date it is delivered to the board of directors, and the handover has been completed, ensuring that his departure will not affect the normal operation and management of the company

    Zhitong·
    SH
    688247
    +0.28%
    Zhitong·
    SH
    688247
    +0.28%

    SINOTHERAPEUTICS: New specifications for Sitagliptin Metformin Extended-Release Tablets approved

    SINOTHERAPEUTICS announced that its wholly-owned subsidiary Jiangsu Xuantai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the new specification of Sitagliptin Metformin Sustained-Release Tablets (each tablet contains 50mg of Sitagliptin and 500mg of Metformin Hydrochloride) to be used for the combination treatment of adult patients with type 2 diabetes

    Zhitong·
    SH
    688247
    +0.28%
    Zhitong·
    SH
    688247
    +0.28%
    © 2026 Longbridge｜Disclaimer